Omeros Co. (OMER) Expected to Announce Earnings of -$0.72 Per Share

Wall Street analysts predict that Omeros Co. (NASDAQ:OMER) will post earnings per share (EPS) of ($0.72) for the current quarter, according to Zacks. Two analysts have issued estimates for Omeros’ earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.70). Omeros reported earnings of ($0.07) per share in the same quarter last year, which would indicate a negative year over year growth rate of 928.6%. The company is scheduled to announce its next earnings results on Thursday, November 8th.

On average, analysts expect that Omeros will report full-year earnings of ($2.67) per share for the current financial year, with EPS estimates ranging from ($2.71) to ($2.62). For the next fiscal year, analysts expect that the company will report earnings of ($1.13) per share, with EPS estimates ranging from ($2.04) to ($0.22). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Omeros.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $1.84 million. Omeros’s quarterly revenue was down 90.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.33) EPS.



OMER has been the topic of a number of research reports. HC Wainwright set a $34.00 price target on Omeros and gave the company a “buy” rating in a report on Wednesday, August 29th. ValuEngine upgraded Omeros from a “hold” rating to a “buy” rating in a report on Friday, July 6th. BidaskClub upgraded Omeros from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 17th. Maxim Group boosted their price target on Omeros from $25.00 to $32.00 and gave the company a “buy” rating in a report on Friday, August 10th. Finally, MED restated a “reduce” rating on shares of Omeros in a report on Monday, July 23rd. One analyst has rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $27.56.

Shares of Omeros stock opened at $15.27 on Thursday. The stock has a market capitalization of $784.73 million, a PE ratio of -19.33 and a beta of 3.49. Omeros has a one year low of $8.36 and a one year high of $27.00.

In related news, VP Marcia S. Kelbon sold 7,529 shares of the company’s stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $25.75, for a total transaction of $193,871.75. Following the sale, the vice president now owns 227,645 shares in the company, valued at $5,861,858.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 12.10% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlueMountain Capital Management LLC bought a new stake in Omeros during the second quarter worth about $118,000. Quad Cities Investment Group LLC bought a new stake in Omeros during the second quarter worth about $161,000. Belpointe Asset Management LLC bought a new stake in Omeros during the second quarter worth about $204,000. Cubist Systematic Strategies LLC bought a new stake in Omeros during the second quarter worth about $274,000. Finally, Lesa Sroufe & Co bought a new stake in Omeros during the second quarter worth about $310,000. Institutional investors and hedge funds own 48.17% of the company’s stock.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Recommended Story: Technical Analysis of Stocks, How Can It Help

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply